Plasvacc
24/7 HELP HOTLINE WITHIN AUSTRALIA 1800 752 762
  • Home
  • Products
    • Products overview
    • Equiplas
    • Equiplas-R
    • Equiplas-E
    • Caniplas
    • Caniplas E
    • CaniPRBC
    • Camelplas
    • Diagnostic Kits
  • How to buy
  • Technology
    • Plasma Therapy
    • Collection process
    • Thawing instructions
    • Product usage
    • Storage
  • Research
    • Scientific papers
    • White papers
    • Background papers
  • About
    • Company overview
    • Animal ethics
    • Plasvacc team
    • Regional commitment
  • Blog
  • Contact

Ensuring Optimal Outcomes For Foals Faced With Rhodococcus Equi

Home» Equine » Ensuring Optimal Outcomes For Foals Faced With Rhodococcus Equi

Ensuring Optimal Outcomes For Foals Faced With Rhodococcus Equi

What is Rhodococcus equi?

A bacterium found in soil worldwide, Rhodococcus equi (R. equi) is a common cause of bronchopneumonia in foals between 3 weeks and 5 months of age.

While the survival rate of R equi pneumonia is upwards of 70% with appropriate therapy, the case fatality rate without therapy is a staggering 80%.

A leading cause of premature death in foals, R. equi infection, or “Rattles” as it’s commonly known, progresses slowly, with foals often not showing clinical signs until the disease has become severe and the mortality risks become greater. At this stage even successful outcomes can lead to life-long complications.

As outlined by the UC Davis School of Veterinary Medicine, the first clinical signs may only present as a slightly increased respiratory rate and mild fever. These easy-to-miss indications are often missed entirely or ignored, allowing the condition to progress undiagnosed until further clinical signs present, including:

  • Decreased appetite
  • Lethargy
  • Fever
  • Tachypnea
  • Increased effort of breathing characterized by nostril-flaring and increased abdominal effort
The Equiplas R Advantage

With just one unit administered right after birth and followed up with another unit one month later, hyperimmune plasma such as Equiplas R has been proven to be a very effective aid in the prevention of Rhodococcus equi in foals. Download study.

Still offering all of the same benefits afforded by Equiplas, Equiplas R also confers protection against R. equi bacteria thanks to donor animals who have been hyperimmunized with the most effective R. equi vaccine available. Accordingly, Equiplas R equine plasma is extremely rich in specific antibodies to Virulence associated protein A (VapA) known to be the major virulence factor of Rhodococcus equi.

While it’s easy to see preventative care as simply another added expense to the already expensive foaling process, Equiplas R is instead an investment in the long-term health and longevity of animals in your care. As veterinarians know, preventing an illness or infection is both safer and less expensive, than to treat it after it has already compromised a patient’s health.

With Equiplas R, not only do you protect your foals against the risks from Failure of Passive Transfer (FPT) or Partial Failure of Passive Transfer (PFPT), but you also greatly reduce the risk of later infection from Rhodococcus equi.

For more information on preventing R. equi infection in your foals, be sure to check out the Equiplas-R product page.

Comments are closed.

FoalsBestStart.com
Want the best for your dog?
See more products

About us

Plasvacc manufactures and distributes high quality hyperimmunised blood plasma products used to supplement the immune response system in animals. Plasma therapy shortens the course of treatments, reduces hospitalisation periods and lessens the quantity of drugs required to treat a variety of medical conditions.

SIGN UP FOR OUR MAILING LIST





    Contact us

    • Telephone: +61 7 5463 7600
    • Technical Support: 1-800-PLASMA | 1-800-752762
    • plasmail@plasvacc.com
    • Contact Us
      • ✉
      • 
      • 
      • 
    • Products
      • Equiplas
      • Equiplas-R
      • Equiplas-E
      • Caniplas
      • Caniplas E
      • CaniPRBC
      • Camelplas
      • Diagnostic Kits
    • How to buy
      • Wholesalers
    • Company overview
      • Plasvacc team
      • Animal ethics
      • Regional commitment
    • Research
      • Scientific papers
      • Background papers
      • White papers
    • Technology
      • Plasma therapy
      • Collection process
      • Thawing Instructions
      • Product usage
      • Storage

    (c) 2012 Plasvacc | All Rights Reserved | privacy policy

    Manage Cookie Consent
    We use cookies to optimise our website and our service.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    Preferences
    {title} {title} {title}